- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00620295
Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors
Phase I Study of Bortezomib and Gemcitabine in Elderly Patients With Solid Tumors (X05227)
RATIONALE: Bortezomib may stop the growth of solid tumors by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bortezomib together with gemcitabine may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of bortezomib and gemcitabine in treating older patients with advanced solid tumors.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
OBJECTIVES:
Primary
- To determine the maximum tolerated dose of weekly bortezomib and gemcitabine in treating elderly patients with advanced solid tumors.
Secondary
- To characterize the quantitative and qualitative toxicities of bortezomib and gemcitabine in these patients.
- To obtain preliminary information about the anti-tumor activity of bortezomib and gemcitabine.
- To characterize gemcitabine and metabolite pharmacokinetics in patients receiving concurrent bortezomib therapy.
OUTLINE: This is a phase I dose escalation study of bortezomib and gemcitabine.
Patients receive gemcitabine intravenously (IV) over 30 minutes followed 1 hour later by bortezomib IV over 3-5 seconds on days 1 and 8. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of gemcitabine and bortezomib until the maximum tolerated dose of the combination is determined.
Blood is collected periodically for pharmacokinetic and pharmacogenetic studies.
After completion of study treatment, patients are followed every 3 months for up to 1 year.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 1
Kontakte und Standorte
Studienorte
-
-
Minnesota
-
Minneapolis, Minnesota, Vereinigte Staaten, 55455
- Masonic Cancer Center at University of Minnesota
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
Histologically or cytologically confirmed diagnosis of advanced non-hematologic malignancy, including any of the following:
- Breast cancer
- Lung cancer
- Colon cancer
- Pancreatic cancer
- Head and neck cancer
- Sarcoma
Must have failed or become intolerant to prior standard therapy and is no longer likely to respond to such therapy (for all diseases except pancreatic cancer)
- Pancreatic cancer patients may be enrolled with no prior therapy requirements since gemcitabine is the current standard of care 1st line therapy
- Measurable or nonmeasurable disease
- Concurrent enrollment in the University of Minnesota study "Population Pharmacokinetics and Pharmacogenetics of Gemcitabine in Adult Patients with Solid Tumors" (Human Subjects Code 0508M72989) required
- ECOG performance status of 0-1
- Absolute neutrophil count ≥ 1,500/mm³
- Platelet count ≥ 100,000/mm³
- Hemoglobin ≥ 10 g/dL
- Bilirubin ≤ 1.5 times upper limit of normal (ULN)
- Alkaline phosphatase ≤ 3.0 times ULN (5 times ULN if liver has tumor involvement)
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 times ULN (5 times ULN if liver has tumor involvement)
- Calculated or measured creatinine clearance > 30 mL/minute
- Fertile patients must use effective contraception during and for 3 months after study participation
- Recovered from all prior therapy
- Prior systemic chemotherapy, immunotherapy, or biological therapy allowed
- At least 3 months since prior bortezomib and/or gemcitabine
- At least 2 weeks since prior systemic therapy
- At least 3 weeks since prior investigational agents (for reasons other than the treatment of cancer)
- At least 2 weeks since prior radiotherapy
Exclusion Criteria:
- Symptomatic brain metastases
- Serious concomitant medical or psychiatric disorders (e.g., active infection or uncontrolled diabetes) that, in the opinion of the investigator, would compromise the safety of the patient or compromise the patient's ability to complete the study
- Myocardial infarction within the past 6 months
- New York Heart Association (NYHA) Class III or IV heart failure
- Uncontrolled angina
- Severe uncontrolled ventricular arrhythmias
- Electrocardiographic evidence of acute ischemia or active conduction system abnormalities
- Peripheral neuropathy ≥ grade 2
- Known hypersensitivity to bortezomib, boron or mannitol
- Prior radiotherapy to ≥ 25% of the bone marrow
- Prior radiotherapy to the whole pelvis
- Concurrent filgrastim (G-CSF) or other hematologic support during course 1 of study treatment
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Gemcitabine / Bortezomib
Gemcitabine will be administered as a 30 minute intravenous infusion at the patient's assigned dose on day 1 and day 8 of a 21 day cycle. Bortezomib will be given 1 hour after gemcitabine by IVP over 3 to 5 seconds followed by a standard saline on days 1 and 8 of a 21 day treatment cycle until disease progression or for a maximum of 6 cycles. |
Bortezomib will be given 1 hour after gemcitabine by intravenous pyelogram (IVP) over 3 to 5 seconds followed by a standard saline flush or through a running intravenous (IV) line at the patient's assigned dose (1.0 up to 1.8 mg/m^2) on days 1 and 8 of a 21 day treatment cycle until disease progression or for a maximum of 6 cycles.
Andere Namen:
Gemcitabine will be administered as a 30 minute intravenous infusion at the patient's assigned dose (800 up to 1000 mg/m^2) on day 1 and day 8 of a 21 day cycle.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Maximum tolerated dose of bortezomib and gemcitabine
Zeitfenster: Day 21 (Week 3 - Cycle 1)
|
A minimum of a 3 week period (1 cycle) must be completed by all patients within a dose level before dose escalation to the next level may occur.
A cycle is defined as treatment day 1 and 8 with follow-up through day 21.
|
Day 21 (Week 3 - Cycle 1)
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Toxicity
Zeitfenster: 30 Days after Last Treatment
|
Toxicity will be graded using the NCI's Common Terminology Criteria for Adverse Events (CTCAE 3.0)
|
30 Days after Last Treatment
|
Disease response as measured by RECIST criteria
Zeitfenster: Week 4
|
The best overall response is the best response recorded from the start of treatment until disease progression/recurrence, taking as reference for progressive disease the smallest measurements recorded since the treatment began.
|
Week 4
|
Characterization of gemcitabine and metabolite pharmacokinetics (as part of co-enrollment in Population Pharmacokinetics and Pharmacogenetics of Gemcitabine in Adult Patients with Solid Tumors")
Zeitfenster: Pre-Dose
|
Pharmacokinetics will be done in conjunction with the dosing day 1 of cycle 1 whenever possible.
|
Pre-Dose
|
Mitarbeiter und Ermittler
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
- rezidivierender Brustkrebs
- rezidivierender nicht-kleinzelliger Lungenkrebs
- rezidivierender kleinzelliger Lungenkrebs
- rezidivierender Prostatakrebs
- rezidivierender Dickdarmkrebs
- rezidivierender Bauchspeicheldrüsenkrebs
- Eierstockkrebs
- rezidivierendes Osteosarkom
- recurrent head and neck cancer
- recurrent uterine cancer
- recurrent kidney cancer
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Verdauungssystems
- Erkrankungen der Atemwege
- Neubildungen nach histologischem Typ
- Neubildungen
- Lungenkrankheit
- Urologische Neubildungen
- Urogenitale Neoplasmen
- Neubildungen nach Standort
- Nierenerkrankungen
- Urologische Erkrankungen
- Adenokarzinom
- Karzinom
- Neubildungen, Drüsen und Epithelien
- Genitale Neubildungen, weiblich
- Erkrankungen des endokrinen Systems
- Eierstockerkrankungen
- Adnexerkrankungen
- Gonadenstörungen
- Neoplasmen des Verdauungssystems
- Neoplasmen der endokrinen Drüse
- Genitale Neubildungen, männlich
- Prostataerkrankungen
- Neubildungen der Atemwege
- Thoraxneoplasmen
- Erkrankungen der Bauchspeicheldrüse
- Nierentumoren
- Karzinom, Nierenzelle
- Kopf-Hals-Neubildungen
- Prostataneoplasmen
- Lungentumoren
- Eierstocktumoren
- Neoplasmen der Bauchspeicheldrüse
- Physiologische Wirkungen von Arzneimitteln
- Molekulare Mechanismen der pharmakologischen Wirkung
- Antiinfektiva
- Antivirale Mittel
- Enzym-Inhibitoren
- Antimetaboliten, antineoplastisch
- Antimetaboliten
- Antineoplastische Mittel
- Immunsuppressive Mittel
- Immunologische Faktoren
- Gemcitabin
- Bortezomib
Andere Studien-ID-Nummern
- CDR0000586510
- UMN-2006LS040 (Andere Kennung: CPRC, University of Minnesota)
- UMN-X05227 (Andere Kennung: Millennium Pharm., Inc.)
- x464 (Andere Kennung: Eli Lilly & Co.)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur bortezomib
-
The First Affiliated Hospital of Soochow UniversityUnbekanntMultiples Myelom durch Labortests nachgewiesenChina
-
Zhongnan HospitalRekrutierungAkute myeloische Leukämie | BortezomibChina
-
Weill Medical College of Cornell UniversityGlaxoSmithKline; Millennium Pharmaceuticals, Inc.AbgeschlossenNon-Hodgkin-LymphomVereinigte Staaten
-
International Extranodal Lymphoma Study Group (IELSG)BeendetLymphom, Schleimhaut-assoziiertes lymphatisches GewebeSchweiz
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Millennium Pharmaceuticals, Inc.AbgeschlossenKopf-Hals-Krebs | Neubildungen des zentralen Nervensystems | Hirntumor | GebärmutterhalskrebsVereinigte Staaten
-
Dana-Farber Cancer InstituteBeth Israel Deaconess Medical Center; Brigham and Women's Hospital; Millennium...AbgeschlossenLymphoplasmatisches Lymphom | Waldenströms MakroglobulinämieVereinigte Staaten
-
OncotherapeuticsMillennium Pharmaceuticals, Inc.BeendetMultiples MyelomVereinigte Staaten
-
Janssen-Cilag International NVAbgeschlossen
-
University of ArkansasMillennium Pharmaceuticals, Inc.BeendetMultiples MyelomVereinigte Staaten